Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...
Sarepta halts three studies testing gene therapy for muscle disorder
Sarepta Therapeutics said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment.
BioSpace3d
Sarepta’s Duchenne Gene Therapy Placed on Hold in Europe Pending Death Investigation
The European Medicines Agency asked for three clinical trials to be placed on hold until the exact cause of death of a US ...
Fierce Pharma3d
UPDATE: After patient death, Sarepta and Roche pause 3 trials of gene therapy Elevidys in Europe
In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...
The Pharma Letter3d
EMA halts Sarepta’s DMD gene therapy trial after patient death
The European Medicines Agency has temporarily suspended enrollment and dosing in a Phase II trial of Sarepta Therapeutics' ...
AOL3d
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
In March, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.
Explore more
Investor's Business Daily on MSN3d
Sarepta Dives On 'Another Unfortunate Development' For Its Gene Therapy
Sarepta stock tumbled Thursday after European officials put all studies of the company's gene therapy, Elevidys, on hold.
Sarepta’s Gene Therapy Under Scrutiny After Patient Death
The company behind the drug, Sarepta Therapeutics, said that the patient suffered acute liver injury, a known side effect, The Associated Press reported. However, the "severity" of this case had not ...
Sarepta says teen died after its gene therapy treatment
Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare muscular dystrophy.
Investing2d
Sarepta gene therapy trials to resume after safety review
CAMBRIDGE, Mass. - Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a $5.7 billion market cap biotechnology company, announced that clinical trials for its gene therapy ELEVIDYS will resume following a ...